Co-Diagnostics, Inc. to Host 2nd Semiannual Distributor Conference on Sept 10-12
August 21 2019 - 6:30AM
Co-Diagnostics, Inc.
(Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that it
will host the 2nd Semiannual Co-Diagnostics Distributor Conference
on September 10-12, 2019 at the Company’s headquarters in Salt Lake
City, Utah.
Conference attendees consist of current and
potential distributors of the Company’s products, representatives
from government and environmental testing institutions, and private
laboratory customers, attending from countries across Asia,
Africa, and the Latin American/Caribbean region. Sessions and
product demonstrations will involve hands-on laboratory training
and will showcase the advantages of the CoPrimer™ technology in
varying applications. The Conference agenda also includes new
product updates and an introduction to the Company’s custom
next-gen sequencing (NGS) library prep, for which a provisional
patent was filed earlier this year.
Any distributors or organizations interested in
attending should request an invitation from Cameron Gundry,
Co-Diagnostics Head of Commercialization (LATAM/EUR), at:
c.gundry[at]codiagnostics.com.
About Co-Diagnostics,
Inc.:Co-Diagnostics, Inc., a Utah corporation, is a
molecular diagnostics company that develops, manufactures and
markets a new, state-of-the-art diagnostics technology. The
Company’s technology is utilized for tests that are designed using
the detection and/or analysis of nucleic acid molecules (DNA or
RNA). The Company also uses its proprietary technology to design
specific tests to locate genetic markers for use in industries
other than infectious disease and license the use of those tests to
specific customers.
Forward-Looking Statements:
This press release contains
forward-looking statements. Forward-looking statements can be
identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company’s liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company’s products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company’s balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities
laws.
Company Sales
Contact:
Seth
Egan
Head of International
Sales
+1 801-438-1036
#2
s.egan@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024